Long-term treatment outcomes after bevacizumab therapy for macular neovascularization in Caucasian patients with high myopia

Monica Ravenstijn, Caroline C W Klaver, Suzanne Yzer

Research output: Contribution to journalArticleResearchpeer-review

Abstract

PURPOSE: To report long-term treatment outcomes of intravitreal bevacizumab (IVB) in myopic macular neovascularization (MNV).

METHODS: Retrospective analysis of longitudinal, clinical data of high myopic MNV patients treated with IVB. One-hundred-seventeen eyes of 106 patients were followed from first injection up to 12 years. Outcome measures were best-corrected visual acuity (BCVA) change during follow-up and myopic MNV recurrence.

RESULTS: Mean (±SD) baseline BCVA (0.56±0.46 LogMar, 20/80) significantly improved after first treatment (0.33±0.33, 20/50, P<0.001). At 4 years (n= 86) BCVA was no longer significantly better than at baseline (0.55±0.57, P = 0.30) and continued to deteriorate to 0.83±0.76 (20/125) at 10 years (n=27). Of the 27 eyes (23%) who reached 10 years of follow-up, 53% developed MNV-related chorioretinal atrophy (CRA). The cumulative incidence of recurrent myopic MNV was 34% at 2 years and 59% at 5 years. BCVA decrease in eyes with or without recurrent MNV was similar (P=0.58). Patchy CRA (HR 3.0, P=0.02) and subfoveal MNVs (HR 2.5, P=0.048) were significantly associated with recurrent MNV.

CONCLUSION: This retrospective myopic MNV study revealed that visual improvement after IVB injections was not maintained over time. MNV recurrences occurred frequently but did not alter the already poor visual prognosis.

Original languageEnglish
JournalRetina
DOIs
Publication statusE-pub ahead of print - 16 Nov 2022

Fingerprint

Dive into the research topics of 'Long-term treatment outcomes after bevacizumab therapy for macular neovascularization in Caucasian patients with high myopia'. Together they form a unique fingerprint.

Cite this